Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05220956
Other study ID # 21-00784
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2021
Est. completion date December 1, 2024

Study information

Verified date December 2023
Source Johannes Gutenberg University Mainz
Contact Jörn M. Schattenberg, Prof.
Phone 06131-17
Email joern.schattenberg@unimedizin-mainz.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomised controlled study of patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Patients will be trained according to the 10 rules of a healthy nutrition according to the German Association for Nutrition (DGE). One arm will undergo Time-Restricted Feeding (TRF) for 12 weeks. The control arm is not subject to any time restrictions concerning eating. It will be investigated whether TRF improves insulin sensitivity, impacts on metabolic inflammation and reduces liver steatosis.


Description:

Patients are recruited in the Liver Outpatient Clinic of the University Medical Center of Mainz. About 100 patients will be enrolled in this pilot study. Inclusions criteria are exclusions of known causes of liver injury, Body Mass Index (BMI) > 25 kg/m^2, severe steatosis according to CAP ≥ 300 dB/m and absence of advanced fibrosis according to liver stiffness < 13 kPa. Following the written consent, all patients will be trained to undertake a 2-week lead-in period of DGE. Beginning in week 3 (Visit 2), an interventional group and a control group are generated through randomisation. The interventional group is instructed to follow TRF, whereas the control group is not subject to any time restrictions. Both arms will be accompanied for a duration of 12 weeks.TRF diet is based on temporal food consumption between 8:00 a.m. and 16:00 p.m., thus a 16 hour lasting period. After 10 weeks from the completion of the experimental phase (wash-out period), there will be the "end of follow up" visit. The whole duration of the study is 24 weeks (2 weeks lead-in, 12 weeks intervention and 10 weeks post-intervention investigation). Transient elastography (Fibroscan) is conducted at the screening visit, randomization visit, and at weeks 8, end of treatment visit and end of study visit. Spleen stiffness measurement is performed at randomization visit, week 8 and end of treatment visit. There will be 5 visits at the study center (screening, randomization, week 8, end of treatment and end of study) and 2 phone visits (week 6 and week 12). At each visit clinical events, body weight and standard laboratory parameters, identification of the CAP and stiffness values will be collected. Participants will fill in questionnaires capturing quality of life. At randomization visit and end of treatment visit, an OGTT will be performed to assess insulin sensitivity. Adverse events will be recorded. Phone visits are used to survey the safety of patients. Non-adherence to TRF for 2 days per week (20% of the total study period) has been selected as cut off to define treatment failure at per-protocol analysis.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Patients with steady medication during the last 3 months. A diabetes mellitus must not be decompensated (HbA1c <6.5%). Patients with advanced fibrosis - defined about the non-invasive Fibroscan-procedure (Fibroscan >13 kPa) - will not be included. Complete inclusion criteria: 1. Age between 18 and 75 years 2. Body Mass Index (BMI) > 25 kg/m2 3. Grade 3 steatosis evaluated by with CAP = 300 dB/m and exclusion of known causes of liver steatosis 4. Liver elastography < 13 kPa 5. Capability to understand the study and the individual consequences of participation 6. Signed and dated declaration of agreement in the forefront of the study Complete exclusion criteria: 1. Liver cirrhosis 2. Hepatocellular carcinoma or non-curative treated carcinoma 3. Alcohol consumption >20g (female) und >30 g (male)/day 4. Other causes of chronic liver disease (HBV, HCV, HDV, HEV, HIV), autoimmune diseases or chronic cholestatic liver disease, hereditary haemochromatosis, Wilson disease, a-1-Antitrypsin deficiency 5. Medications which cause liver disease or secondary NAFLD (e. g. Tamoxifen, systemic Corticosteroids, Methotrexate, Tetracycline, Estrogens, Valproic acid) 6. Changes in body weight > 5% in the last 6 months 7. Statins and/ or other fat-reducer medications if not taken in steady dosage during at least 4 weeks 8. Uncontrolled diabetes type 2 defined as HbA1c value > 9.0% or insulin depending type 2 diabetes 9. Pregnancy 10. Immunologic or inflammatory disease (e. h. systemic lupus erythematodes) 11. Patients after organ transplantations 12. Missing or lacking consent capability

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Intermittent fasting
One arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
DGE diet
The control arm is not a subject to any time restrictions concerning eating while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.

Locations

Country Name City State
Germany University Medical Center of the Johannes Gutenberg Univeristy Mainz Rheinland-Pfalz

Sponsors (2)

Lead Sponsor Collaborator
Johannes Gutenberg University Mainz University of Turin, Italy

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the impact of TRF on liver steatosis by CAP (dB/m) The primary outcome of interest is a change in CAP value of a least 20 db/m with TRF 12 weeks
Secondary Changes in liver fibrosis by liver stiffness (kPa) under TRF Liver elastography performed as surrogate marker of liver fibrosis 12 weeks
Secondary Changes in FIB-4 as indirect non-invasive tools of liver fibrosis Changes in the surrogate marker of liver fibrosis FIB-4 12 weeks
Secondary Evaluation of changes in direct non-invasive tool of liver fibrosis ELF Performed as surrogate markers of liver fibrosis 12 weeks
Secondary Evaluation of changes in direct marker of liver fibrogenesis PRO-C3 (ng/ml) Performed as surrogate markers of liver fibrosis 12 weeks
Secondary Evaluation of changes in liver-specific quality of life Evaluation of Patient Reported Outcomes using the Chronic Liver Disease Questionnaire (CLDQ). The CLDQ uses 29 items in four domains, each scored on a Likert scale from 1 (all of the time) to 7 (none of the time) representing the frequency of clinical symptoms and emotional problems in the last two weeks. Results are reported in the six subscale scores (abdominal symptoms, fatigue, systemic symptoms, activity, emotional functioning, worry) and a CLDQ overall score. 12 weeks
Secondary Evaluation of changes in insulin sensitivity Changes in insulin sensitivity by indexes derived by HOMA-IR score 12 weeks
Secondary Evaluation of changes in the gut microbiota Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis. 12 weeks
Secondary Evaluation of changes in markers of oxidative stress (AGEs) AGEs as surrogate markers of oxidative stress 12 weeks
Secondary Changes in spleen volume by spleen stiffness under TRF Spleen stiffness performed as surrogate of spleen volume 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT06051669 - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Not yet recruiting NCT05984745 - Effect of CoQ10 on the Outcome of MAFLD Patients Phase 2
Completed NCT02565446 - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram N/A
Not yet recruiting NCT01694342 - Telomere Parameters in Patients With Nonalcoholic Fatty Liver N/A
Completed NCT01464801 - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease N/A
Completed NCT01992809 - Omega 3 Supplementation in Fatty Liver Phase 3
Completed NCT00063635 - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Phase 3
Completed NCT00244569 - Development of a Breath Test for Monitoring Patients With Liver Disease Phase 3
Recruiting NCT03972319 - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study Early Phase 1
Completed NCT03141008 - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Recruiting NCT05125757 - Lifestyle Modification in Psoriatic Patients With Fatty Liver N/A
Recruiting NCT05370053 - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology N/A
Recruiting NCT04371042 - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Recruiting NCT02265276 - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease Phase 3
Completed NCT02347007 - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3